LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

NCT01380730 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

631

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

BIOLOGICAL: Evolocumab
OTHER: Placebo to Evolocumab

Sponsor

Amgen

Collaborators

[object Object]